-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor T cell (CAR-T) therapy, as a disruptive innovative therapy, is booming in China
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T cell product targeting CD19 approved for marketing.
For the treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), it brings a new treatment option for R/R LBCL
.
At present, Achilles has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! On September 8, 2021, the third CCSC-Kylinhui International Connection was successfully held
.
This meeting was fortunate to invite Professor Wang Jianxiang from the Chinese Academy of Medical Sciences Hematology Hospital, EHA Chairman Hamilton Fairley Professor John Gribben, Professor Qiu Lugui from the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Zou Dehui from the Hematology Hospital of the Chinese Academy of Medical Sciences, and Hematology Department of the Chinese Academy of Medical Sciences.
Professor Liu Wei from the Hospital of Medical Sciences, Professor Wang Ying from the Hospital of Hematology of the Chinese Academy of Medical Sciences and many top domestic experts served as conference speakers and discussion guests.
Yikaida® (Akilunza injection) for in-depth discussions and exchanges
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Looking at CAR-T's actual combat experience in lymphoma from real world data.
In this session, Professor John Gribben from the Oncology Department of Hamilton Fairley shared an introduction entitled "Real world experience of CAR-T cells in lymphoma"
.
Professor John Gribben gave a detailed introduction to the ZUMA series of studies.
The ZUMA 1 study compared the results of studies in the United States and Europe and showed consistent effectiveness of CAR-T treatment; the ZUMA 7 study has now reached the primary efficacy endpoint; The ZUMA 12 and ZUMA 2 studies both showed good remission rates, with ORR reaching 85% and 93%, respectively; the ZUMA 5 study compared with the SCHOLAR 5 study showed a clear survival advantage
.
Facing the promising application prospects of CAR-T therapy, Professor John Gribben also put forward his own opinions on toxicity management and specific clinical applications, and shared two real cases for everyone to learn
.
Kirin Meta-Treatment Center Introduction In this session, Professor Liu Wei from the Hospital of Hematology, Chinese Academy of Medical Sciences gave a brief introduction to the National Lymphoma and Myeloma Clinical Research Center jointly established by the Chinese Academy of Medical Sciences and Peking Union Medical College
.
I have counted the research honors of the center from 1985 to 2019, and made a detailed introduction to the center's organizational structure, research projects, and current results
.
Regarding CAR-T treatment, Professor Liu Wei introduced the current CD19 CAR-T treatment for relapsed and refractory non-Hodgkin’s lymphoma, the CD19 CAR-T treatment for relapsed large B-cell lymphoma, and the failure of CD19 CAR-T treatment.
The results of research on CD20 CAR-T treatment for patients and CAR-T treatment for relapsed and refractory multiple myeloma
.
Looking at the future of CAR-T cell transformation in the field of hematological diseases.
In this session, Professor Wang Ying from the Hospital of Hematology of the Chinese Academy of Medical Sciences shared an introduction entitled "The translation of HI CAR T-cell therapy"
.
Professor Wang Ying combed the development history of HI CAR-T from 2016 to 2020, and introduced in detail the research results of CD19 CAR-T in the treatment of relapsed and refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.
An epoch-making cancer treatment model led by T therapy, and emphasizes the importance of the full management of CAR-T therapy
.
The wheel of CAR-T treatment has not stopped.
Professor Wang Ying also introduced the animal experiment of CD123-CD33 combined with CAR-T in the treatment of acute myeloid leukemia.
There are more CAR-T studies on CD5, CD7, Kit, etc.
In
.
CAR-T has a promising future in the field of blood diseases
.
To discuss this session, Professor Wang Ying from the Hospital of Hematology, Chinese Academy of Medical Sciences asked questions about the comparison of the efficacy of CAR-T treatment with different drugs, the comparison of the efficacy between CAR-T treatment and transplantation, and the follow-up treatment of patients who failed CAR-T treatment Problem
.
Regarding the comparison of different treatment drugs and different treatment methods, Professor John Gribben believes that due to the influence of multiple factors, one cannot simply say that a certain treatment drug or treatment method is better.
The current understanding of CAR-T treatment drugs is still developing In China, more research progress is needed to analyze this issue in depth
.
For patients who have failed CAR-T treatment, Professor John Gribben hopes that the treatment of specific antibodies will allow the patients to get remission and then undergo transplantation.
However, the current research is still in progress and the answer is still uncertain
.
Professor Yi Shuhua from the Hospital of Hematology, Chinese Academy of Medical Sciences asked questions about the bridging treatment in the ZUMA 1 study and the problem of drug conversion in the treatment
.
Regarding bridging therapy, Professor John Gribben believes that bridging therapy can be used for patients with disease progression, but the current attitude towards bridging therapy is still relatively conservative.
At the same time, bridging therapy can also be tried for patients who are still in remission
.
Regarding the issue of drug switching, Professor John Gribben said that further research results need to be waited to determine which is right and wrong
.
Summary At the end, Professor Wang Jianxiang made a summary of the meeting
.
Professor Wang thanked Fosun Kate for the invitation, thanked the experts participating in the conference for their meticulous preparation, and hoped that CAR-T treatment could bring more hope to Chinese patients
.
The meeting ended successfully in the heated discussion of experts and scholars! Poke "read the original text", we make progress together
.
On June 22, 2021, Yikaida® (Akilunza injection) was officially approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T cell product targeting CD19 approved for marketing.
For the treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), it brings a new treatment option for R/R LBCL
.
At present, Achilles has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! On September 8, 2021, the third CCSC-Kylinhui International Connection was successfully held
.
This meeting was fortunate to invite Professor Wang Jianxiang from the Chinese Academy of Medical Sciences Hematology Hospital, EHA Chairman Hamilton Fairley Professor John Gribben, Professor Qiu Lugui from the Hematology Hospital of the Chinese Academy of Medical Sciences, Professor Zou Dehui from the Hematology Hospital of the Chinese Academy of Medical Sciences, and Hematology Department of the Chinese Academy of Medical Sciences.
Professor Liu Wei from the Hospital of Medical Sciences, Professor Wang Ying from the Hospital of Hematology of the Chinese Academy of Medical Sciences and many top domestic experts served as conference speakers and discussion guests.
Yikaida® (Akilunza injection) for in-depth discussions and exchanges
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
Looking at CAR-T's actual combat experience in lymphoma from real world data.
In this session, Professor John Gribben from the Oncology Department of Hamilton Fairley shared an introduction entitled "Real world experience of CAR-T cells in lymphoma"
.
Professor John Gribben gave a detailed introduction to the ZUMA series of studies.
The ZUMA 1 study compared the results of studies in the United States and Europe and showed consistent effectiveness of CAR-T treatment; the ZUMA 7 study has now reached the primary efficacy endpoint; The ZUMA 12 and ZUMA 2 studies both showed good remission rates, with ORR reaching 85% and 93%, respectively; the ZUMA 5 study compared with the SCHOLAR 5 study showed a clear survival advantage
.
Facing the promising application prospects of CAR-T therapy, Professor John Gribben also put forward his own opinions on toxicity management and specific clinical applications, and shared two real cases for everyone to learn
.
Kirin Meta-Treatment Center Introduction In this session, Professor Liu Wei from the Hospital of Hematology, Chinese Academy of Medical Sciences gave a brief introduction to the National Lymphoma and Myeloma Clinical Research Center jointly established by the Chinese Academy of Medical Sciences and Peking Union Medical College
.
I have counted the research honors of the center from 1985 to 2019, and made a detailed introduction to the center's organizational structure, research projects, and current results
.
Regarding CAR-T treatment, Professor Liu Wei introduced the current CD19 CAR-T treatment for relapsed and refractory non-Hodgkin’s lymphoma, the CD19 CAR-T treatment for relapsed large B-cell lymphoma, and the failure of CD19 CAR-T treatment.
The results of research on CD20 CAR-T treatment for patients and CAR-T treatment for relapsed and refractory multiple myeloma
.
Looking at the future of CAR-T cell transformation in the field of hematological diseases.
In this session, Professor Wang Ying from the Hospital of Hematology of the Chinese Academy of Medical Sciences shared an introduction entitled "The translation of HI CAR T-cell therapy"
.
Professor Wang Ying combed the development history of HI CAR-T from 2016 to 2020, and introduced in detail the research results of CD19 CAR-T in the treatment of relapsed and refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.
An epoch-making cancer treatment model led by T therapy, and emphasizes the importance of the full management of CAR-T therapy
.
The wheel of CAR-T treatment has not stopped.
Professor Wang Ying also introduced the animal experiment of CD123-CD33 combined with CAR-T in the treatment of acute myeloid leukemia.
There are more CAR-T studies on CD5, CD7, Kit, etc.
In
.
CAR-T has a promising future in the field of blood diseases
.
To discuss this session, Professor Wang Ying from the Hospital of Hematology, Chinese Academy of Medical Sciences asked questions about the comparison of the efficacy of CAR-T treatment with different drugs, the comparison of the efficacy between CAR-T treatment and transplantation, and the follow-up treatment of patients who failed CAR-T treatment Problem
.
Regarding the comparison of different treatment drugs and different treatment methods, Professor John Gribben believes that due to the influence of multiple factors, one cannot simply say that a certain treatment drug or treatment method is better.
The current understanding of CAR-T treatment drugs is still developing In China, more research progress is needed to analyze this issue in depth
.
For patients who have failed CAR-T treatment, Professor John Gribben hopes that the treatment of specific antibodies will allow the patients to get remission and then undergo transplantation.
However, the current research is still in progress and the answer is still uncertain
.
Professor Yi Shuhua from the Hospital of Hematology, Chinese Academy of Medical Sciences asked questions about the bridging treatment in the ZUMA 1 study and the problem of drug conversion in the treatment
.
Regarding bridging therapy, Professor John Gribben believes that bridging therapy can be used for patients with disease progression, but the current attitude towards bridging therapy is still relatively conservative.
At the same time, bridging therapy can also be tried for patients who are still in remission
.
Regarding the issue of drug switching, Professor John Gribben said that further research results need to be waited to determine which is right and wrong
.
Summary At the end, Professor Wang Jianxiang made a summary of the meeting
.
Professor Wang thanked Fosun Kate for the invitation, thanked the experts participating in the conference for their meticulous preparation, and hoped that CAR-T treatment could bring more hope to Chinese patients
.
The meeting ended successfully in the heated discussion of experts and scholars! Poke "read the original text", we make progress together
